Sun Sep 15 13:42:55 UTC 2024: ## Institutional Investors Show Interest in Invivyd, Inc. (IVVD) Amidst Recent Earnings Miss

**New York, NY – September 15, 2024** – Invivyd, Inc. (NASDAQ: IVVD), a commercial-stage biopharmaceutical company focused on antibody-based solutions for infectious diseases, has seen increased interest from institutional investors. Cornercap Investment Counsel Inc. acquired a new stake in the company during the second quarter, purchasing 77,753 shares valued at approximately $86,000.

Several other institutional investors also modified their holdings in Invivyd. SG Americas Securities LLC grew its stake by 198.6% in the second quarter, while Rhumbline Advisers significantly increased its position by 4,434.1% during the same period. Tidal Investments LLC and Bank of New York Mellon Corp also acquired new stakes in Invivyd during the first and second quarters, respectively.

This surge in institutional interest comes amidst a recent earnings miss for Invivyd. The company reported a loss of $0.40 per share for the second quarter, falling short of analysts’ expectations of $0.37. Revenue also came in below estimates at $2.26 million compared to the projected $4.91 million.

Despite the earnings shortfall, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on Invivyd shares. This optimism is likely tied to the company’s focus on the rapidly growing infectious disease market and its unique INVYMAB platform.

Invivyd’s stock opened at $1.15 on Friday, with a 52-week low of $0.81 and a 52-week high of $5.20. The company currently has a market capitalization of $137.36 million.

For more information on institutional holdings and insider trades for Invivyd, Inc., visit HoldingsChannel.com.

Read More